Glycobiomarkers are valuable for disease diagnostics, monitoring and prognostics with greater sensitivity and specificity than the currently used biomarkers. For liver diseases diagnostics, Wisteria floribunda agglutinin (WFA)-positive human Mac-2-binding protein, fucosylated haptoglobin, vitronectin, antithrombin III, WFA-positive colony stimulating factor 1 receptor and fucosylated hemopexin were recently reported to be promising glycobiomarkers, including fucosylated serum paraoxonase 1 and fucosylated GP73 in our previous studies. Large-scale validation and clinical trials of most glycobiomarkers are urgently needed for crossing the boundary from the laboratory into routine clinical use.
An ideal biomarker for diseases is a measurable indicator of a specific biological state, which should possess high specificity, high sensitivity, organ specificity and reliable predictive value [1, 2] . Aberrant glycosylation are associated with various physiological and pathological status including malignant transformation and metastasis [3, 4] . Glycans are essentially metabolic products and their biosyntheses are more significantly affected by disease states than protein production [5] . Thus, glycoprotein-based biomarkers (glycobiomarkers) have emerged as promising biomarkers for a wide range of diseases by utilizing the specific changes in glycan structures on a glycoprotein. Use of glycobiomarkers could provide more specificity, if this disease-associated glycan structure is not present in other phenotypes [6] . Given the current technology development, sensitivity of detection and assay robustness may not be an issue. The proportion of the Lens culinaris agglutinin (LCA)-reactive fraction of α-fetoprotein (AFP-L3) has already been approved by the US Food and Drug Administration for liver cancer diagnosis [7] . Table 1 gave some examples of potential glycobiomarkers for liver diseases diagnosis.
Recently, the WFA-positive human Mac-2-binding protein (WFA + -M2BP) was shown to be a novel liver fibrosis glycobiomarker with a unique fibrosis-related glycoalteration, which is also a useful marker for the risk of developing hepatocelluar carcinoma (HCC) and for predicting the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C patients [8] [9] [10] [11] [12] . Combination of M2BP and fucosylated haptoglobin (Fuc-Hp) could distinguish nonalcoholic steatohepatitis from nonalcoholic fatty liver disease patients [13] . Hp is an acidic glycoprotein tetramer that is mainly secreted in the liver. A unique pattern of Hp glycoforms comprising hyper-and hypo-sialylated fucosylated species was found in the HCC patients [14] . Zhu et al. [15] and Asazawa et al. [16] reported that it could serve as a potential marker for early detection and prediction of HCC progression. Vitronectin (VTN) is also known as candidate glycobiomarker of HCC [17, 18] . 14 unique N-linked glycans corresponding to 27 unique N-linked glycopeptides were characterized at three N-glycosites present in VTN. Among them, the abundance ratio of two representative glycoforms (fucosyl vs non-fucosyl) was significantly increased in HCC plasma [19] . The NeuAc2 HexNAc4 Hex5 modification of antithrombin III was also observed to be related to the tumorigenesis and progression of HCC [17] . Colony stimulating factor 1 receptor (CSF1R) was identified as a potential liver cirrhosis (LC) marker and WFA-reactive CSF1R (WFA + -CSF1R) was established as a novel possible glycobiomarker candidate for evaluation of LC [20] . Elevation of fucosylated hemopexin has been shown to be a glycobiomarker for HCC using lectin-fluorophore-linked immunosorbent assay [21] .
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In our studies, serum paraoxonase 1 (PON1) was discovered to be highly fucosylated and sialylated in HCC compared with that in LC patients [22] . Then, ELISA Index (OD value of fucosylated PON1/OD value of protein PON1) was introduced to indicate PON1 fucosylation level on its protein level (Fuc-PON1). The evaluation of this assay demonstrated its superior diagnosis of early HCC patients that proved serum Fuc-PON1 was a potential glycobiomarker for distinguishing early HCC from LC patients, even for HCC patients with low AFP levels [23] . We also used multiple lectin assays for pre-clinical evaluation of Fuc-GP73, which could act as a potential glycobiomarker complementary to AFP-L3 for discrimination of HCC from LC patients. Combining Fuc-GP73 and AFP-L3 greatly improved the diagnostic accuracy (AUC=0.953) and the diagnostic values were 94.4% sensitivity at 88.9% specificity [24] . Furthermore, alpha-1-acid glycoprotein, transferrin, alkaline phosphatase, gamma-glutamyltransferase and serum cholinesterase have been reported to be possible glycobiomarkers of liver diseases for several years. However, most glycobiomarkers are still under development and have not crossed the boundary from the laboratory into routine clinical use.
In summary, aberrant glycosylation of proteins is a well-known hallmark of many diseases and glycobiomarkers are valuble for disease diagnostics, monitoring and prognostics with greater sensitivity and specificity than the currently used biomarkers. Further, large-scale validation and clinical trials of promising glycobiomarkers are urgently needed for diagnostic power of these glycoproteins.
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